{
    "id": 4000,
    "name": "ovary transitional cell carcinoma",
    "source": "DOID",
    "definition": "An ovarian epithelial cancer that derives_from epithelial transitional cells. [url:https\\://www.ncbi.nlm.nih.gov/pmc/articles/PMC3362466/]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "2637",
        "4002"
    ],
    "termId": "DOID:4000",
    "evidence": [
        
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02178722",
            "title": "A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4088,
                    "therapyName": "Epacadostat + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04034927",
            "title": "Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                },
                {
                    "id": 8289,
                    "therapyName": "Olaparib + Tremelimumab",
                    "synonyms": null
                }
            ]
        }
    ]
}